skip to Global Navigation Bar skip to main content


homeHome > About Us > Press Release > News

News

News Content
Daewoong’s ‘NABOTA’ submitted the form to change clinical test plans in China.
Date 2019-01-07 Hit 784
list
News List
Prev DAEWOONG Pharmaceutical’s New Year’s greetings: “The year 2019 will be the first year of our challenge to be a global healthcare group”
Next Daewoong Pharmaceutical’s ‘NABOTA’ becomes the first Korea-made Botulinum Toxin to obtain US FDA approval